
Sight Sciences (SGHT) Stock Forecast & Price Target
Sight Sciences (SGHT) Analyst Ratings
Bulls say
Sight Sciences Inc. is positioned for a positive financial outlook due to its potential for robust revenue growth, driven by accelerating market share gains in the minimally invasive glaucoma surgery (MIGS) sector and increased adoption of the TearCare System. The company's investment thesis highlights that its Surgical Glaucoma segment is expected to maintain growth consistent with the overall MIGS market, ensuring a solid revenue foundation. Additionally, improvements in earnings per share (EPS) for 2025 and 2026 indicate a trend toward increased profitability, further reinforcing the optimistic financial projections for the company.
Bears say
Sight Sciences Inc. continues to project 2025 revenues in the range of $72-76 million while anticipating a mid-single-digit percentage decline in Surgical Glaucoma revenue for the third quarter of 2025 compared to the prior year. The company faces significant risks, including increasing competition in the minimally invasive glaucoma surgery (MIGS) market, slow progress in securing insurance coverage for its TearCare product, and a persistent elevated cash burn rate that may hinder financial stability. Furthermore, although management has reduced its adjusted operating expense guidance for 2025 to $95-99 million from a previous $101-105 million, the expected $12 million in annualized savings may not sufficiently offset the declining revenue expectations.
This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.
Sight Sciences (SGHT) Analyst Forecast & Price Prediction
Start investing in Sight Sciences (SGHT)
Order type
Buy in
Order amount
Est. shares
0 shares